Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management and over 180 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, Novira, CytomX and Civitas Therapeutics. Canaan is currently investing in a $675 million fund focused on early stage IT and healthcare startups. The fund's healthcare focus includes early stage biopharma, medical devices, and digital health.
Tim Shannon will be in attendance on October 27th to provide an overview presentation of Canaan's areas of interest and best practices when applying for funding. Tim will be on hand to meet with a handful of applicants one-on-one after the presentation.
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 6th.
Canaan Partners Participating Representative:
Tim Shannon | General Partner, Canaan Partners
For more than 25 years, Tim Shannon has been an entrepreneur, executive, researcher, professor, and practicing physician in pulmonary and critical care medicine. A Canaan investor since 2009, Tim uses years of operating experience to help companies grow from their earliest stages to funded companies creating value through partnerships, M&A and IPOs. Most recently, Tim was startup CEO and currently serves as the Chairman of Arvinas, named by Fierce Biotech as a Fierce 15 company of 2015. Tim was one of the early institutional investors and remains on the board of CytomX Therapeutics, which completed a $92 million initial public offering in October 2015 (NASDAQ: CTMX). He was a co-lead Series A investor in Civitas Therapeutics, which was acquired by Acorda Therapeutics in October 2014 for $525 million, and a lead Series A investor in Novira Therapeutics, Inc. which was acquired by Johnson & Johnson in December 2015. In addition, he serves on the boards of IDEAYA Biosciences, NextCure, Spyryx Biosciences, Vivace Therapeutics and VaxInnate Corporation. Prior to Canaan, Tim was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer. Earlier he was the senior vice president and head of global clinical development for Bayer's Pharmaceutical Business Group. Tim began his career as assistant professor of the pulmonary and critical care division at Yale University School of Medicine. Tim received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College. Read more here.
Connect with Tim:
Presentation & Lunch
CA$ 35 | General Public
CA$ 50 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 26th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on October 6th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ Toronto
MaRS Centre, West Tower
661 University Ave, Suite 1300 [13th Floor]
When & Where
JLABS @ Toronto
JLABS, part of Johnson & Johnson Innovation, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.